Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?

MLA

Puneet Singh, et al. “Biomarkers in Immune Checkpoint Inhibition Therapy for Cancer Patients: What Is the Role of Lymphocyte Subsets and PD1/PD-L1?” Translational Medicine Communications, vol. 4, no. 1, Feb. 2019, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s41231-019-0032-9.

APA

Puneet Singh, Paul de Souza, Kieran F. Scott, Bruce M. Hall, Nirupama D. Verma, Therese M. Becker, James W. T. Toh, Mila Sajinovic, & Kevin J. Spring. (2019). Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1? Translational Medicine Communications, 4(1), 1–13. https://doi.org/10.1186/s41231-019-0032-9

Chicago

Puneet Singh, Paul de Souza, Kieran F. Scott, Bruce M. Hall, Nirupama D. Verma, Therese M. Becker, James W. T. Toh, Mila Sajinovic, and Kevin J. Spring. 2019. “Biomarkers in Immune Checkpoint Inhibition Therapy for Cancer Patients: What Is the Role of Lymphocyte Subsets and PD1/PD-L1?” Translational Medicine Communications 4 (1): 1–13. doi:10.1186/s41231-019-0032-9.